Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients

The aim of this study was to determine whether baseline serum C-reactive protein (CRP) levels were associated with overall survival in patients with metastatic prostate cancer in the Chinese population. A total of 135 patients with metastatic prostate cancer were retrospectively reviewed. Both Kaplan-Meier product-limit method and multivariable analysis by Cox regression model were used to assess the prognostic role of serum CRP levels on overall survival of patients with metastatic prostate cancer. There were 51 patients (37.8 %) with higher values of baseline serum CRP levels (a parts per thousand yen10 mg/L). Kaplan-Meier product-limit method and log-rank test showed that patients with high serum CRP level (a parts per thousand yen10 mg/L) had significantly worse overall survival than those patients with normal serum CRP level (< 10 mg/L) (P < 0.001). The multivariable analysis by Cox regression model further showed that high serum CRP level (a parts per thousand yen10 mg/L) was a significantly independent predictor of overall survival (hazard ratio (HR) = 2.39; 95 % confidence interval (95 % CI) 1.56-2.39, P < 0.001). In addition, high Gleason score (a parts per thousand yen8) also was an independent predictor of overall survival (HR = 1.80; 95 % CI 1.16-2.79, P = 0.008). In conclusion, serum CRP level is useful to predict the prognosis of metastatic prostate cancer patients, and high serum CRP level is a significantly independent predictor of worse overall survival.